Cases of myositis following COVID-19 vaccination are rare but documented. The clinical spectrum includes mild inflammatory myopathy, dermatomyositis, immune-mediated necrotising myopathy, and overlap syndromes. The relationship remains under study.
Findings from the Literature
-
A 2023 review collected 49 cases of inflammatory myositis after COVID-19 vaccination. Muscle involvement was most frequent (~80 %), followed by skin manifestations (~53 %) and interstitial lung disease (~35 %). Most patients received mRNA vaccines.
-
Case reports have described anti-MDA5 dermatomyositis, overlap syndromes, and myositis combined with myocarditis following mRNA vaccination.
-
Symptoms usually onset days to weeks post-vaccine. Workup often reveals elevated CK, MRI muscle oedema, EMG myopathy patterns, and in some cases, myositis-specific antibodies (e.g. anti-MDA5, anti-PM/Scl). Biopsy, when done, shows inflammation, necrosis, and MHC-I upregulation.
-
Treatment generally involves high-dose corticosteroids, often with IVIG or immunosuppressants (methotrexate, mycophenolate, rituximab). Many patients improve, though anti-MDA5 + ILD cases carry higher risk.
Consent, Payments & Research Limitations
-
Under UK law and GMC guidance, informed consent must be obtained before vaccination, meaning patients should receive disclosure of benefits, risks, and alternatives.
-
Many report that full informed consent was not provided, particularly regarding long-term risks, rare adverse events, or ingredient details.
-
In the UK, GP surgeries are paid £7.54 per COVID-19 vaccine dose (plus £10 for housebound patients) and £9.58 per influenza vaccine, along with reimbursement of vaccine cost.
-
Because these payments underpin vaccine delivery further independent research may be underprioritised or underfunded, given the conflict between findings that might lower uptake and maintaining vaccine programme revenue.
Historical / Regulatory Notes
-
COVID-19 vaccination was initially not recommended for younger age groups until safety data were established.
-
Clinical trials and post-marketing surveillance continued well after roll-out; for example, long-term safety data collection extended into January 2023 and beyond.
Key Takeaways
- Myositis after COVID-19 vaccination is documented but rare.
- Onset typically occurs within days to weeks of vaccination.
- Management with immunosuppressants often yields improvement.
- Informed consent is mandated but often reportedly remains incomplete in practice.
- GP payment per vaccine (COVID: £7.54 + housebound supplement; flu: £9.58) introduces systemic incentives.
- Funding priorities and institutional alignment may suppress or disincentivise independent adverse event research.
- Further prospective, independent studies are needed to assess incidence, mechanisms, and long-term safety.
Key References & Research Links
-
Syrmou V, et al. COVID-19 vaccine-associated myositis: comprehensive review and case report. Immunologic Research, 2023. — PMC article: pmc.ncbi.nlm.nih.gov/articles/PMC10018601/
-
González D, et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. PMC article: pmc.ncbi.nlm.nih.gov/articles/PMC9166182/
-
Bolla E, et al. New-onset anti-MDA5 dermatomyositis following COVID-19 vaccination. PMC article: pmc.ncbi.nlm.nih.gov/articles/PMC11082759/
-
Ding Y, et al. Inflammatory myopathy following coronavirus disease vaccination. PMC article: europepmc.org/article/pmc/pmc9634642
-
Klein CR, et al. Anti-MDA5 autoantibodies predict clinical dynamics of dermatomyositis after SARS-CoV-2 mRNA vaccination. Rheumatology International (open access) — link.springer.com/article/10.1007/s00296-024-05683-5
-
Camargo-Coronel A, et al. Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review. Reumatismo PDF: reumatismo.org/index.php/reuma/article/download/1548/970/7027
-
Reumatismo editorial / commentary: Myositis after SARS-CoV-2 vaccination occurs more frequently than assumed. (Reumatismo, 2023) — reumatismo.org